Looks as if I spoke too soon...$0.25 held in the end.I agree...

Looks as if I spoke too soon...$0.25 held in the end.

I agree that people were probably expecting more sooner from the company, but the approval for the NZ trials were out of the hands of LCT. At least we now have a definite date set for a result. I feel that the directors have delivered on what is in their control which is a positive. Clinical trials progressing well in Russia, increased dosage results on the way in the coming months and possible trials commencing early next year in the US...at least they're not waiting around for NZ and moving forward.

Alot to look forward to in the next financial year.